Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects

Published:2024-04 Issue: Volume:222 Page:116066
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Chen Yizhao,Liu Chong,Fang Yilong,Chen Weile,Qiu Jiaqi,Zhu Mengjuan,Wei Wei,Tu Jiajie

Funder

Anhui Medical University

Anhui Provincial Natural Science Foundation

Anhui Province Department of Education

Publisher

Elsevier BV

Reference109 articles.

1. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T;Liu;Mol. Cancer,2023

2. CAR T-cell therapy in hematological malignancies;Haslauer;Int. J. Mol. Sci.,2021

3. Human Tregs made antigen specific by gene modification: the power to treat autoimmunity and antidrug antibodies with precision;Adair;Front. Immunol.,2017

4. Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections;Zmievskaya;Biomedicines,2021

5. Therapeutic strategies for COVID-19: progress and lessons learned;Li;Nat. Rev. Drug Discov.,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T therapy for ovarian cancer: Recent advances and future directions;Biochemical Pharmacology;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP